What question did this study set out to answer?

To review the landscape of FDA-approved protein kinase inhibitors for oncogenic targets and evaluate landmark clinical trials leading to their regulatory approval.

September 27, 2018Expert Review of Anticancer Therapy

A comprehensive review of protein kinase inhibitors for cancer therapy

View Full Paper

Ask AI

Bookmark

Authors

RKRadhamani Kannaiyan DMDaruka Mahadevan

Discussion

Member takes

Overview

Narrative review demonstrates clinical indications of kinase inhibitors in oncology patients, highlighting the value of biomarker profiling for targeted cancer therapy.

Key Points

To review the landscape of FDA-approved protein kinase inhibitors for oncogenic targets and evaluate landmark clinical trials leading to their regulatory approval.
Cataloged FDA-approved protein kinase inhibitors and their respective oncologic indications authorized through December 2017.
Conducted PubMed literature searches to analyze the mechanistic roles of oncogenic protein kinases in carcinogenesis and identify landmark clinical trials supporting regulatory approvals.
Identified numerous kinase inhibitors approved across multiple cancer types, demonstrating a transformative shift toward targeted molecular therapies in oncology.
Highlighted essential future directions, including the integration of biomarker profiling to optimize patient selection, rational sequencing of available inhibitors, and clinical evaluation in adjuvant settings.

Cite This Study

Kannaiyan et al. (2018) studied this question.

synapsesocial.com/papers/6a156ddf814bf8ec9a4e942b https://doi.org/10.1080/14737140.2018.1527688

View Full Paper

Ask AI

Bookmark

September 27, 2018Expert Review of Anticancer Therapy

A comprehensive review of protein kinase inhibitors for cancer therapy

View Full Paper

Ask AI

Bookmark

Authors

RKRadhamani Kannaiyan DMDaruka Mahadevan

Discussion

Member takes

Overview

Narrative review demonstrates clinical indications of kinase inhibitors in oncology patients, highlighting the value of biomarker profiling for targeted cancer therapy.

Key Points

To review the landscape of FDA-approved protein kinase inhibitors for oncogenic targets and evaluate landmark clinical trials leading to their regulatory approval.
Cataloged FDA-approved protein kinase inhibitors and their respective oncologic indications authorized through December 2017.
Conducted PubMed literature searches to analyze the mechanistic roles of oncogenic protein kinases in carcinogenesis and identify landmark clinical trials supporting regulatory approvals.
Identified numerous kinase inhibitors approved across multiple cancer types, demonstrating a transformative shift toward targeted molecular therapies in oncology.
Highlighted essential future directions, including the integration of biomarker profiling to optimize patient selection, rational sequencing of available inhibitors, and clinical evaluation in adjuvant settings.

Cite This Study

Kannaiyan et al. (2018) studied this question.

synapsesocial.com/papers/6a156ddf814bf8ec9a4e942b https://doi.org/10.1080/14737140.2018.1527688

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark